BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease? United European Gastroenterol J 2020;8:753-4. [PMID: 32640933 DOI: 10.1177/2050640620942641] [Reference Citation Analysis]
2 Chen K, Lou Y, Zhu Y. Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis. Evid Based Complement Alternat Med 2021;2021:5548764. [PMID: 34211567 DOI: 10.1155/2021/5548764] [Reference Citation Analysis]
3 Goulart RDA, Barbalho SM, Rubira CJ, Araújo AC, Lima VM, Buchaim RL, Guiguer EL. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2020;14:1171-9. [DOI: 10.1080/17474124.2020.1808460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 James JP, Riis LB, Malham M, Høgdall E, Langholz E, Nielsen BS. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer. Int J Mol Sci 2020;21:E7893. [PMID: 33114313 DOI: 10.3390/ijms21217893] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
5 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]